These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1992637)

  • 1. Kawasaki-like syndrome after treatment with mesalazine.
    Waanders H; Thompson J
    Am J Gastroenterol; 1991 Feb; 86(2):219-21. PubMed ID: 1992637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tubulointerstitial nephritis caused by mesalazine (5-ASA) agents].
    Smilde TJ; van Liebergen FJ; Koolen MI; Gerlag PG; Assmann KJ; Berden JH
    Ned Tijdschr Geneeskd; 1994 Dec; 138(51):2557-61. PubMed ID: 7830805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
    Bayerdörffer E; Bock H
    Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease.
    Kawakami T; Fujita A; Takeuchi S; Muto S; Soma Y
    J Am Acad Dermatol; 2009 Jan; 60(1):146-9. PubMed ID: 19103366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease].
    García-Díaz M; Nevado L; Berenguer A; Bureo JC; Bureo P; Sáenz de Santamaría J
    Gastroenterol Hepatol; 1995 Jan; 18(1):18-21. PubMed ID: 7621266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.
    Turunen U; Elomaa I; Anttila VJ; Seppälä K
    Scand J Gastroenterol; 1987 Sep; 22(7):798-802. PubMed ID: 2890198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease].
    Netzer P
    Schweiz Med Wochenschr; 1995 Dec; 125(50):2438-42. PubMed ID: 8553032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic inflammatory intestinal disease and nephritis].
    Behrens R; Ruder H
    Klin Padiatr; 1992; 204(1):61-4. PubMed ID: 1346814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatitis induced by mesalamine.
    Erdkamp F; Houben M; Ackerman E; Breed W; van Spreeuwel J
    Neth J Med; 1992 Aug; 41(1-2):71-3. PubMed ID: 1407243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
    Ewe K; Becker K; Ueberschaer B
    Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute pancreatitis due to 5-aminosalicylic acid].
    Romero Castro R; Jiménez Sáenz M; Pellicer Bautista FJ; Domínguez Palomo S; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 1991 Mar; 79(3):219-21. PubMed ID: 2043409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
    Lachaux A; Le Gall C; Loras-Duclaux I; Aboufadel A; Hermier M
    Arch Pediatr; 1997 Feb; 4(2):144-6. PubMed ID: 9097825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
    Rutgeerts P
    Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease.
    Stoschus B; Meybehm M; Spengler U; Scheurlen C; Sauerbruch T
    J Hepatol; 1997 Feb; 26(2):425-8. PubMed ID: 9059966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mesalazine].
    Netzer P
    Dtsch Med Wochenschr; 1996 Jan; 121(1-2):42. PubMed ID: 8565806
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pentasa (mesalazine) and pregnancy].
    Jonville-Bera AP; Soyez C; Fignon A; Moraine C; Berger C; Autret E
    Therapie; 1994; 49(5):443-5. PubMed ID: 7855761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
    Iaquinto G; Sorrentini I; Petillo FE; Berardesca G
    Ital J Gastroenterol; 1994 Apr; 26(3):145-7. PubMed ID: 8061342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalazine: a global safety evaluation.
    Brimblecombe R
    Scand J Gastroenterol Suppl; 1990; 172():66. PubMed ID: 1972297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.